Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Surgery-radiotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma
1 trial -
T cell injection targeting CD7 chimeric antigen receptor
The First People's Hospital of Lianyungang
T-ALL
1 trial -
T, 260 mg/m2, paclitaxel for injection (albumin-bound)
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
TCM+ Routine Therapy
The First People's Hospital of Lianyungang
Proteinuria
1 trial -
TEA plus GDMT
The First People's Hospital of Lianyungang
Heart Failure With Reduced Ejection Fraction
1 trial -
TNK plus standard medical treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Ischemic Stroke
1 trial -
TPO-RA
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Primary Immune Thrombocytopenic Purpura
1 trial -
TRT
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Tacrolimus or Cyclosporine A
The First People's Hospital of Lianyungang
Immune Tolerance
1 trial -
Tacrolimus+Mycophenolate mofetil
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lupus Nephritis
1 trial -
Tadalafil
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pulmonary Arterial Hypertension (PAH)
1 trial -
Tadalafil 2.5Mg Tab
Hospital Authority, Hong Kong
Erectile Dysfunction
1 trial -
Tafolecimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Coronary Syndrome
1 trial -
Tailored AI echocardiogram analysis and reporting system
Hospital Authority, Hong Kong
Heart Failure
1 trial -
Tamsulosin Hydrochloride
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Benign Prostatic Hyperplasia
1 trial -
Tegoprazan-amoxicillin dual therapy
The First People's Hospital of Lianyungang
Helicobacter Pylori Infection
1 trial -
Telmisartan
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hypertension
1 trial -
Tenofovir Disoproxil Fumarate
The First People's Hospital of Lianyungang
Hepatitis B, Chronic
1 trial -
Terbutaline
Hospital Authority, Hong Kong
Nonreassuring Fetal Status
1 trial -
Terlipressin
The First People's Hospital of Lianyungang
Terlipressin
1 trial -
Terlipressin treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Septic Shock
1 trial -
Tests of the expression of CXCL3 in various tissues
The First People's Hospital of Lianyungang
Diabetic Kidney Disease (DKD)
1 trial -
Thalidomide
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma
1 trial -
The specific drug comes from "GINA (2024)"
The First People's Hospital of Lianyungang
Asthma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources